Dergiler / Trends in pediatrics / 2022 / Cilt: 3 - Sayı: 1

New Treatment Modalities in Hemophilia

Sayfa
1–4
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Although celluler gene therapy is very hopeful and successful phase-3 studies are reported, gene therapy for hemophilia will not be mentioned in this review.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Hemophilia is a single gene disorder and as a genetical coagulation system problem it is a life-long bleeding disorder.
📊
Temel Bulgular & Veri:Even though routine treatment modalities as plasma-derived and then recombinant factor concentrates available for last 50 years, unmet needs is continuing for hemophilia therapy.
💡
Sonuç & Katkı:Although celluler gene therapy is very hopeful and successful phase-3 studies are reported, gene therapy for hemophilia will not be mentioned in this review.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Hemophilia is a single gene disorder and as a genetical coagulation system problem it is a life-long bleeding disorder. Even though routine treatment modalities as plasma-derived and then recombinant factor concentrates available for last 50 years, unmet needs is continuing for hemophilia therapy. Gold standart treatment is regularly prophylactic FVIII/FIX infusions. However, life-long and frequent intra-venous infusions become medical burden for patients and families. New agents as enhanced half-life (EHL) factor concentrates and non-factor therapies which are able to be used subcutaneously are very hopeful. In this review, EHL factor concentrates, FVIII mimetic agents and re-balancing therapies will be discussed. Although celluler gene therapy is very hopeful and successful phase-3 studies are reported, gene therapy for hemophilia will not be mentioned in this review.

🔖

Bu Makaleye Atıf Yap

KAVAKLI, K. (2022). New Treatment Modalities in Hemophilia. Trends in pediatrics, Cilt: 3 - Sayı: 1, 1–4. https://ajindex.com/articles/598876

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Mannucci PM, Tuddenham E. The hemophilias- from royal genes to gene therapy. N Eng J Med. 2001;344:1773-79
  2. Srivastava A, Santagostino E, Dougal A, et al. WFH Guidelines for the management of hemophilia. 3rd ed. Hemophilia 2020;26(Suppl 6):1-158
  3. Mancuso ME, Male C, Kenet G, Kavakli K, et al. Prophylaxis in children with hemophilia in an evolving tretment landscape. Haemophilia. 2021;27:889-96
  4. Malhan S, Öksüz E, Antmen B, et al. Cost of hemophilia A in Turkey: An economical disease burden analysis. J Med Econ. 2021;24:1052-59
  5. Leebeck FW, Miesbach W. Gene therapy for hemophilia. A review on clinical benefits, limitations and remaining isssues. Blood. 2021;138:923-31
  6. Ragni M. Hemophilia as a blueprint for gene therapy. Science. 2021;374:40-1
  7. Ar C, Balkan C, Kavakli K. Extended half-life coagulation factors: A new era in the management of hemophilia patients. Turk J Hematol. 2019;36:141-54
  8. Meunier S, Ehrenfort E, Kavakli K. Safety and efficacy of a glyco-PEGylated rFVIII (turoctococ alpha pegol) in pediatric patients with severe hemophilia-A. Thromb Haemost. 2017;117:1705-13
  9. Konkle B, Shapiro A, Kulkarni R, et al. BIVV-001 fusion protein as FVIII replacement therapy for hemophilia-A. N Eng J Med. 2020;383:1018-27
  10. Young G, Dunn A, Pipe S. Emicizumab for hemophilia-A with FVIII inhibitors. Exp Rev Hemat. 2018;11:835-46
  11. Lenting P, Dennis C. Emicizumab, a specific antibody recognizing coagulation factors IX and X: How dose it actually compare to FVIII. Blood. 2017;130:2463-8
  12. Oldenburg J, Mahlangu J, Kui B, et al. Emicizumab prophylaxis in hemophilia-A with inhibitors. N Eng J Med. 2017;377:809-18
  13. Young G, Sidonio R, Liesner R, et al. HAVEN-2 updated analysis: Multicenter open label phase-3 study to evaluated efficacy safety and PKs of SC emicizumab prophylaxis in pediatric patients with hemophilia-A and inhibitors. Blood. 2017;130(Suppl1):85
  14. Mahlangu J, Oldenburg J, Negrier C, et al. Emicizumab prophylaxis in patients who have hemophilia-A without inhibitors. N Eng J Med. 2018;379:811-22
  15. Pipe S, Shima M, Lahle M, et al. Efficacy, safety and PKs of Emicizumab prohylaxis given every 4 weeks in people with hemophilia-A: Multi centered, open-label, non-randomised phase- 3 study. Lancet Hematol. 2019;19:3054-7
  16. Kjellev S, Ostergaard H, et al. Mim-8 a next generation FVIII mimetic bi-specific antibody potently restores the hemostatic capacity in hemophilia a settings in vitro and in-vivo. Blood. 134;(Su